Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Modular Peptide Probe for Pre/Intra/Postoperative Therapeutic to Reduce Recurrence in Ovarian Cancer
ACS Nano ( IF 15.8 ) Pub Date : 2020-11-11 , DOI: 10.1021/acsnano.9b09818 Jun Dai 1 , Yong Cheng 2 , Jun Wu 2 , Quan Wang 2 , Wenwen Wang 1 , Juliang Yang 2 , Zujin Zhao 3 , Xiaoding Lou 2 , Fan Xia 2 , Shixuan Wang 1 , Ben Zhong Tang 3
ACS Nano ( IF 15.8 ) Pub Date : 2020-11-11 , DOI: 10.1021/acsnano.9b09818 Jun Dai 1 , Yong Cheng 2 , Jun Wu 2 , Quan Wang 2 , Wenwen Wang 1 , Juliang Yang 2 , Zujin Zhao 3 , Xiaoding Lou 2 , Fan Xia 2 , Shixuan Wang 1 , Ben Zhong Tang 3
Affiliation
|
Even with optimal surgery, 80% of patients with ovarian cancer will have recurrence. Adjuvant therapy can reduce the recurrence of tumors; however, the therapeutic effect is still not prominent. Herein, we designed a modular peptide probe (TCDTMP), which can be self-assembled into nanoparticles (NPs) by loading in miR-145-5p or VEGF-siRNA. In vivo, (1) preoperative administration of TCDTMP/miR-145-5p ensured that NPs were adequately accumulated in tumors through active targeting and increased the expression of miR-145-5p in tumors, thereby inducing tumor cell apoptosis. (2) Intraoperatively, most of the tumors were removed, while the microscopic residual tumors were largely eliminated by TCDTMP/miR-145-5p-mediated photodynamic therapy (PDT). (3) Postoperatively, TCDTMP/VEGF-siRNA were given for antiangiogenesis therapy, thus delaying the recurrence of tumors. This treatment was named a preoperative (TCDTMP/miR-145-5p)||intraoperative (surgery and PDT)||postoperative (TCDTMP/VEGF-siRNA) therapeutic system and abbreviated as the PIP therapeutic system, which reduced the recurrence of ovarian cancer in subcutaneous tumor models, intraperitoneal metastasis models, and patient-derived tumor xenograft models. Our findings provide a therapeutic system based on modular peptide probes to reduce the recurrence of ovarian cancer after surgery, which provides a perspective for the surgical management of ovarian cancer.
中文翻译：
模块化肽探针可降低卵巢癌的术前/术中/术后治疗
即使采用最佳手术，80％的卵巢癌患者也会复发。辅助治疗可以减少肿瘤的复发；但是，治疗效果仍然不明显。在这里，我们设计了一种模块化的肽探针（T CD TMP），可以通过加载到miR-145-5p或VEGF-siRNA中而自组装成纳米颗粒（NP）。在体内，（1）术前给予T CD TMP / miR-145-5p可确保通过主动靶向在肿瘤中充分积累NP，并增加miR-145-5p在肿瘤中的表达，从而诱导肿瘤细胞凋亡。（2）在术中，大部分肿瘤被切除，而显微镜下残留的肿瘤大部分被T CD消除。TMP / miR-145-5p介导的光动力疗法（PDT）。（3）术后给予T CD TMP / VEGF-siRNA进行抗血管生成治疗，从而延缓了肿瘤的复发。该治疗方法被称为术前（T CD TMP / miR-145-5p）||术中（手术和PDT）||术后（T CD TMP / VEGF-siRNA）治疗系统，简称为PIP治疗系统，减少了皮下肿瘤模型，腹膜内转移模型和患者源性肿瘤异种移植模型中卵巢癌的复发。我们的发现提供了一种基于模块化肽探针的治疗系统，以减少手术后卵巢癌的复发，这为卵巢癌的外科治疗提供了前景。
更新日期：2020-11-25
中文翻译：
模块化肽探针可降低卵巢癌的术前/术中/术后治疗
即使采用最佳手术，80％的卵巢癌患者也会复发。辅助治疗可以减少肿瘤的复发；但是，治疗效果仍然不明显。在这里，我们设计了一种模块化的肽探针（T CD TMP），可以通过加载到miR-145-5p或VEGF-siRNA中而自组装成纳米颗粒（NP）。在体内，（1）术前给予T CD TMP / miR-145-5p可确保通过主动靶向在肿瘤中充分积累NP，并增加miR-145-5p在肿瘤中的表达，从而诱导肿瘤细胞凋亡。（2）在术中，大部分肿瘤被切除，而显微镜下残留的肿瘤大部分被T CD消除。TMP / miR-145-5p介导的光动力疗法（PDT）。（3）术后给予T CD TMP / VEGF-siRNA进行抗血管生成治疗，从而延缓了肿瘤的复发。该治疗方法被称为术前（T CD TMP / miR-145-5p）||术中（手术和PDT）||术后（T CD TMP / VEGF-siRNA）治疗系统，简称为PIP治疗系统，减少了皮下肿瘤模型，腹膜内转移模型和患者源性肿瘤异种移植模型中卵巢癌的复发。我们的发现提供了一种基于模块化肽探针的治疗系统，以减少手术后卵巢癌的复发，这为卵巢癌的外科治疗提供了前景。
京公网安备 11010802027423号